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Endothelial cells differentiate from mesoderm-derived precursors to initiate the earliest events in vascular
development. Although the signaling events that regulate the successive steps of vascular development are
known in some detail, the transcriptional processes that regulate the first steps in vasculogenesis are not well
defined. We have studied the regulatory mechanisms of flk1 expression as a model to understand the upstream
events in endothelial cell differentiation, since flk1 is the earliest marker of endothelial precursors. Using a
variety of biochemical approaches, we identified a cis-acting element in the first intron of the flk1 gene that is
required for endothelium-dependent expression in transgenic reporter gene assays. Using the yeast one-hybrid
system, we identified HoxB5 as the transcription factor that binds this cis-acting element, the HoxB5-binding
element (HBE). HoxB5 mRNA colocalized with flk1 expression in differentiating embryoid bodies, and HoxB5
potently transactivated the flk1 promoter in an HBE-dependent fashion in transient-transfection assays.
Overexpression of HoxB5 led to expansion of flk1 angioblasts in differentiating embryoid bodies and in-
creased the number of PECAM (platelet-endothelial cell adhesion molecule)-positive primitive blood vessels.
HoxB5 is necessary and sufficient to activate the cell-intrinsic events that regulate the differentiation of
angioblasts and mature endothelial cells from their mesoderm-derived precursors.
The vascular endothelium is a continuous surface that forms
a boundary between circulating hematopoietic cells and the
underlying mural vascular cells. In addition to its barrier func-
tion, the endothelium integrates signals from the circulation to
modulate vascular tone and is a major determinant of the
inflammatory process by regulating activation and adhesion of
white blood cells. Appropriate activation of the endothelium is
also the necessary proximate event for growth of new blood
vessels from existing vessels during development and in phys-
iologic and pathological conditions via the process of angio-
genesis. Even earlier in development, the first blood vessels
form in situ by migration and differentiation of endothelial
precursors, or angioblasts, via the process of vasculogenesis.
Although angiogenesis and vasculogenesis have distinguishing
features, the signaling events that regulate these processes are,
in most cases, overlapping.
The cellular and developmental processes that coordinate
endothelial cell differentiation are only now being well ex-
plained. The earliest marker of cells fated to the endothelial
lineage is the receptor for vascular endothelial growth factor
(VEGF), flk1 (VEGFR-2; the human homolog is also known
as KDR). flk1 is first expressed at day 7.0 postconception (p.c.)
in the mouse embryo in the yolk sac mesoderm and in the
lateral plate mesoderm of the embryo proper (50). Deletion of
flk1 by homologous recombination results in absence of both
endothelial and hematopoietic cells, suggesting that early pop-
ulations of flk1-expressing cells define a bipotential precursor
for these two lineages (41). This conclusion has been sup-
ported by the identification of flk1 blast colony-forming cells
that give rise to hematopoietic and endothelial lineage progeny
in in vitro assays (11). These early bipotential cells have been
termed hemangioblasts. Identification of hemangioblasts in
vivo, however, has proven to be an elusive task, and their
existence remains controversial (14, 26). The weight of evi-
dence seems to be in favor of a hemangioblast at some point
during development, although the extent of its spatiotemporal
distribution is unclear. In any event, it is accepted that flk1
cells define a major population of angioblasts and that defin-
itive endothelial cells maintain flk1 expression, whereas hema-
topoietic populations do not.
In contrast to other lineages, our appreciation of the tran-
scriptional events that determine commitment down the endo-
thelial developmental pathway is limited. The basic helix-loop-
helix protein SCL/tal-1 is the transcription factor most closely
linked to the earliest stages of endothelial cell differentiation.
flk1 and SCL/tal-1 are coexpressed in presumptive angioblasts
within the lateral plate mesoderm (14), although temporally
SCL/tal-1 expression follows that of flk1 (17), and targeted
deletion of SCL/tal-1 affects early hematopoietic differentia-
tion and angiogenic remodeling of the yolk sac but not endo-
thelial differentiation (35, 39, 42). However, expression of
SCL/tal-1 under the flk1 promoter in flk1-null embryos and
embryonic stem cells results in partial rescue of endothelial cell
development in vivo and in vitro, suggesting that a combina-
torial genetic effect of flk1 and SCL/tal-1 in establishing the
endothelial lineage after flk1 expression is initiated in meso-
derm-derived progenitors (16). VEZF1/DB1 is a zinc finger
transcription factor that is also specifically expressed during
early stages of endothelial differentiation (49). However,
VEZF1/DB1 does not regulate the earliest set of angioblast
markers (such as flk1), at least in transient-transfection assays
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(1). VEZF1/DB1 more likely participates in later events in
vascular development, although a complete analysis of its func-
tion—including its deletion by homologous recombination—
has yet to be reported.
We have used formal analysis of the flk1 promoter as a
model to understand the proximate events in the commitment
of lateral mesoderm precursors to the endothelial lineage. The
5-flanking sequence of the human flk1 gene supports high-
level reporter gene expression in cell culture (32), and the
transcription factors Sp1, TFII-I, and GATA-2 are implicated
in regulation via the flk1 promoter (30, 33, 48). However, large
fragments of the flk1 5-flanking sequence from either the
mouse or human genes do not support reporter gene expres-
sion in transgenic mice (C. Patterson, unpublished observa-
tions), indicating that other elements are necessary for expres-
sion within the endothelium. Recently, the Breier laboratory
has identified a 510-bp enhancer-like element in the distal
portion of the first intron of the mouse flk1 gene that confers
endothelium-specific expression in vivo (23), indicating that
proteins regulating flk1 expression through this element are
likely bona fide upstream contributors to the determination of
the endothelial cell lineage. Binding sites for GATA and Ets
family members have been tested deductively based on se-
quence analysis of this fragment and are indeed necessary for
its activity (24). However, proteins from these families are
likely to be only ancillary factors in flk1 expression, since ge-
netic studies have not implicated any of them as being clearly
upstream of angioblast determination. (Interestingly, putative
SCL/tal-1 sites are present in the flk1 element defined by these
studies, but they are dispensable for reporter gene expression
in transgenic mice [24].)
As an alternative approach, we have searched for potential
upstream transcriptional regulators of endothelial cell differ-
entiation by using an unbiased, inductive approach. Using a
combination of molecular, biochemical, and genetic ap-
proaches, we identified HoxB5 (a member of the classical and
highly conserved family of homeobox proteins) as a potent
transcriptional regulator of flk1 expression. In addition, we
have found that the HoxB5-binding site in the flk1 gene is
required for expression within the vascular endothelium during
development. Most importantly, we show here that overexpres-
sion of HoxB5 increases the number of angioblasts during
embryonic stem cell differentiation (as determined by measur-
ing the number of flk1 cells at early stages of angioblast
differentiation in this system) and also the number of mature
endothelial cells, which form primitive blood vessels and ex-
press platelet-endothelial cell adhesion molecule (PECAM).
These studies unexpectedly place HoxB5 at a very early step in
the process of angioblast differentiation and indicate that
HoxB5 is both necessary and sufficient to regulate flk1 expres-
sion.
MATERIALS AND METHODS
In vitro DNase I footprinting. In vitro DNase I footprinting was performed as
described previously (33). Overlapping DNA fragments containing bp 1 to 256
and bp 138 to 511 of the mouse flk1 first intronic enhancer were labeled with
[-32P]dGTP by using the Klenow fragment of DNA polymerase I. Approxi-
mately 10,000 cpm of the labeled DNA fragment was incubated with 25 g of
nuclear extract or bovine serum albumin (BSA) and 1 g of poly(dI-dC)-poly(dI-
dC) for 25 min on ice and then for 2 min at room temperature. Samples were
treated with increasing doses of DNase I (0.0005 to 0.005 Kunitz units with BSA
and 0.005 to 0.05 Kunitz units with nuclear extract) at room temperature for 2
min. Samples were analyzed on 6% (wt/vol) denaturing polyacrylamide-urea gels
as described previously (47).
EMSA. Mouse myocardial endothelial cells (MECs), Py-4-1 mouse hemangi-
oma endothelial cells, C166 mouse embryonic yolk sac endothelial cells, bEnd.3
mouse endothelial cells, and C2C12 mouse myoblast cells were grown in Dul-
becco modified Eagle medium with 10% fetal calf serum. (MECs and C166 cells
were generous gifts from Robert Auerbach.) Preparation of nuclear extract and
electrophoretic mobility shift assay (EMSA) were performed as previously de-
scribed (33). The probe consisted of annealed synthetic 46-bp complementary
oligonucleotides corresponding to bp 150 to 195 of the mouse flk1 first-intronic
enhancer or mutated oligonucleotides as indicated. Prior to annealing, the oli-
gonucleotides were labeled with [-32P]ATP by using polynucleotide kinase. A
typical binding reaction contained 20,000 cpm of DNA probe, 0.5 g of poly(dI-
dC)-poly(dI-dC), 25 mM HEPES (pH 7.9), 40 mM KCl, 3 mM MgCl2, 0.1 mM
EDTA, 1 mM dithiothreitol, 10% glycerol, and 5 g of nuclear extract in a final
volume of 20 l. The reaction was incubated at room temperature for 20 min and
fractionated on a 6% native polyacrylamide gel in 0.5 Tris-borate-EDTA
buffer. To determine the specificity of the DNA-protein complexes, we per-
formed competition assays by using a molar excess of unlabeled wild-type oligo-
nucleotides. To characterize specific DNA-binding proteins, a recombinant glu-
tathione S-transferase (GST)-HoxB5 fusion protein was used in place of nuclear
extract, with or without preincubation with anti-GST antibody (or an isotype-
specific control antibody) for 3 h at 4°C before adding probe.
Generation of transgenic mice. The mouse flk1 promoter-reporter transgene
consisted of the mouse 940-bp (640 to 299) flk1 promoter fragment followed
by the LacZ reporter gene, and 510 bp of the first intronic enhancer, with or
without the M4 mutation, as depicted in Fig. 1A. Transgenic mice were gener-
ated by microinjection of purified transgene DNA into pronuclei of single-cell
fertilized eggs as described previously (22). Transgenic positive embryos were
identified by PCR analysis of yolk sac genomic DNA by using lacZ-specific
primers (sense, 5-CAACTTAATCGCCTTGCCTTGCAGCAC-3; antisense,
5-CTTCCAGATAACTGCCGTCACT-3) to generate a 500-bp PCR product.
Whole-mount lacZ staining of embryos derived from injected eggs was per-
formed as described previously (22).
Yeast one-hybrid screening. The one-hybrid library screen was performed
according to the protocol of the manufacturer (Clontech). The pHISi-HBE and
pLacZi/HBE bait plasmids were constructed by using synthetic DNA oligomers
containing three tandem repeats of the flk1 intronic enhancer from bp 164 to 183,
defined by in vitro DNase I footprinting and EMSA. Linear bait plasmids were
integrated into the genome of the yeast YM4271 by homologous recombination.
The yeast strain was then transformed with a pACT2 vector-based mouse em-
bryo day 10.5 p.c. cDNA library (Clontech). About 2  106 yeast transformants
were plated on synthetic complete medium lacking histidine and leucine and
supplemented with 45 mM 3-amino-1,2,4-triazole. Selected clones were sub-
jected to the -galactosidase assay using the colony-lift filter method. Several
negative control plasmids were used in the selection procedure, including the
mutant constructs pHISi-HBEmt and pLacZi-HBEmt, p53Blue containing the
consensus p53 binding site, and p53 containing the murine p53 gene fused to the
GAL4 activation domain. Plasmids from putative positive clones were recovered
from yeast and individually transformed into Escherichia coli DH10B cells for
amplification. To eliminate false-positive results, these plasmids were separately
introduced into yeast cells containing either bait or the p53 binding site, and
transformants were tested for -galactosidase assay. Inserts were sequenced, and
the DNA sequences were used to query the GenBank database.
Transient-transfection assays. MECs were used for transient transfection
assays because they can be reproducibly transfected with high efficiency. Cells
were grown to 40 to 60% confluence in six-well plates and then transfected with
Lipofectamine (Life Technologies), as described previously (1). The cells were
transfected with 1.0 g of pflk1/en3 (which contains sequences from positions
640 to 299 of the mouse flk1 promoter upstream of the luciferase gene and
the 510-bp intronic enhancer downstream) or pflk1/en3mt (containing a 5-bp
mutation within the HoxB5-binding site) with different concentrations (indicated
in Fig. 5) of pECH/HoxB5, pcDNA3/HoxB6, or control vectors. (Hox expression
constructs were generous gifts from Craig Hauser.) To correct for variability in
transfection efficiency, 0.25 g of pCMV-gal was cotransfected in all experi-
ments. At 48 h after transfection, cells extracts were prepared by a detergent lysis
method (Promega). Luciferase activity was measured in duplicates for all sam-
ples. -Galactosidase assay was performed as previously described (32). The
ratio of luciferase activity to -galactosidase activity in each sample served as a
measure of the normalized luciferase activity. The normalized luciferase activity
was expressed as the fold induction. Each construct was transfected at least four
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times, and the data for each construct are presented as the mean 	 the standard
error.
Embryonic stem cells growth and stable transfection. R1 mouse embryonic
stem cells were maintained by growth and passage on gelatinized tissue culture
dishes in maintenance medium containing conditioned medium from human
5637 bladder carcinoma cells. Differentiation was initiated by treating embryonic
stem cell aggregates with dispase and culturing embryoid bodies in differentia-
tion medium (Dulbecco modified Eagle medium-HEPES with 15% lot selected
fetal calf serum, 5 g of gentamicin/ml, and 150 M monothioglycerol). Cells
were grown in bacterial dishes to allow for the formation of cystic embryoid
bodies and then plated on tissue culture plates after 60 h for attachment. At-
tached embryoid bodies were grown under these conditions for the indicated
times (5). To construct the corresponding stably transfected cell lines, the cDNAs
for HoxB5 and HoxB6 were inserted into pcDNA3 (which contains the neomycin
resistance cassette) downstream of the cytomegalovirus (CMV) promoter. Lin-
ear plasmids were electroporated into R1 mouse embryonic stem cells. Stable
FIG. 1. Identification of cis-acting elements in the mouse flk1 first-intronic enhancer. (A) Scheme of mouse flk1 genomic locus and transgenic
construct. A total of 940 bp (positions from 640 to 299) of the 5-flanking sequence of the mouse flk1 gene and 510 bp of the first intronic
enhancer are sufficient to target lacZ expression to the vascular endothelium in transgenic mice. (B) Diagram of the general approach undertaken
to identify cis-acting elements in the mouse flk1 first intronic enhancer. (C) Protein-binding site identification by in vitro DNase I footprinting. A
single footprint, located between bp 150 and 195 in the intronic enhancer, was detected on both sense and antisense strands. The dark line denotes
the putative binding site for DNA-binding proteins. (D) Analysis of cell type differences in DNase I footprinting patterns. The labeled probe was
incubated with nuclear extracts from MECs, Py-4-1, C166, bEnd.3, and C2C12 cells, or BSA prior to digestion with DNase I.
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clones were selected with G418 for 12 days, were screened for transgene expres-
sion by reverse transcription-PCR (RT-PCR), and confirmed by Northern blot-
ting. The specific primers used for HoxB5 were as follows: sense, 5-TCCTCG
GAGCCTGAGGAAGCGGCAAG-3, and antisense, 5-CCCGTCCGGCCCG
GTCATATCATG-3.
RNA preparation and RT-PCR. Total RNA was isolated from cultured cells by
using the High-Pure MiniRNA kit (Roche). All RNA samples were treated with
DNase I before cDNA synthesis to eliminate contaminating genomic DNA.
Equal amounts of RNA were converted to first-strand cDNA with reverse tran-
scriptase and were then amplified with Taq DNA polymerase. (The DNA am-
plification reaction was also carried out without reverse transcriptase to ensure
that amplified bands were not due to contamination by genomic DNA in the
RNA preparations.) The oligonucleotides used for detecting specific cDNA were
as follows: mouse HoxB5 (sense, 5-TCCTCTGAGCCCGAGGAAGCGGCGA
G-3; antisense, 5-CCACTTCATGCGACGGTTCTG-3), flk1 (sense, 5-GGA
ACCTGACTATCCGCAGG-3; antisense, 5-CCTCAACAAAGCCTGAGCT
GG-3); or GAPDH (glyceraldehyde-3-phosphate dehydrogenase; sense, 5-AC
CACAGTCCATGCCATCAC-3; antisense: 5-TCCACCACCCTGTTGCTGT
A-3). GAPDH served as an RNA integrity and normalization control.
Flow cytometry, cell sorting, and immunostaining. Phycoerythrin-conjugated
rat anti-mouse flk1 antibody and rat anti-mouse CD31 (PECAM-1) antibody
were purchased from Becton Dickinson. Alexafluor 488-conjugated goat anti-rat
immunoglobulin G antibody was from Molecular Probes. Differentiated embry-
onic stem cells were trypsinized (when sorted for flk1) or subjected to collage-
nase digestion (when sorted for PECAM-1) to produce a single-cell suspension.
Cells were counted, and equal numbers were stained with an appropriate anti-
body in 0.1% BSA–phosphate-buffered saline for 30 min, washed twice with 0.1%
BSA–phosphate-buffered saline, and then stained with secondary antibody or
analyzed directly on a Becton Dickinson FACSscan by using the Cytomation
Summit software or, alternatively, sorted on a MoFlo instrument (Cytomation).
Dead cells were excluded from the analysis. Immunostaining of cultured cells
with the anti-PECAM-1 antibody was performed as described previously (5).
Images were collected with a Qimaging Retica 1300 digital camera by using
Qcapture and IPlab software.
RESULTS
Mapping of DNA-protein interactions in the flk1 intronic
element. Previous studies have indicated that a 510-bp positive
regulatory element in the 3 end of the mouse flk1 first intron
confers endothelial cell-specific expression on the minimal 5-
flanking sequence in transgenic reporter gene assays (Fig. 1A)
and that binding sites for GATA and Ets family members
contribute to this activity (23, 24). We have confirmed the
activity of this regulatory element by using similar constructs
(data not shown). Because this element has been incompletely
characterized and because neither GATA nor Ets proteins
acting alone are likely to account for the restricted pattern of
flk1 expression, we used a variety of biochemical, molecular,
and genetic approaches to determine the upstream factors
regulating flk1 expression by using an unbiased approach (Fig.
1B). As a first step, we performed in vitro DNase I footprinting
with extracts from C166 embryonic endothelial cells to search
for nuclear protein-binding sites. Although we sequenced the
entire element on both strands, only a single region, located
340 bp upstream of exon 2, was clearly footprinted (Fig. 1C). In
particular, we did not observe nuclear protein binding at con-
sensus GATA, Ets, or SCL/tal-1 sites (23). The binding activity
identified here was present in nuclear extracts from a wide
panel of endothelial cells but, interestingly, nuclear extracts
from C2C12 myoblasts did not footprint this region (Fig. 1D),
suggesting that endothelial cell-specific factor(s) may be re-
sponsible for the footprint.
We performed EMSA to characterize this binding activity
further. Two complexes were identified: a more rapidly migrat-
ing complex that was variably present in endothelial cell nu-
clear extracts, and a more intense, slowly migrating complex
that was present in all endothelial cell nuclear extracts but was
weak or absent in extracts from C2C12 cells (Fig. 2A). In order
to define the binding determinants for this complex with
greater resolution, we created serial mutations within our
EMSA probe (Fig. 2B) and examined the effects of these
mutations on binding activity using C166 nuclear extracts. The
sequential mutations M3, M4, and M5 almost completely abol-
ished binding, whereas other mutants had more subtle effects
on DNA-protein interaction (Fig. 2C). The element identified
by mutagenesis corresponds to a 14-bp sequence containing
bipartite AT-rich stretches flanking an atypical AP1-like ele-
ment that is conserved across species (Fig. 2D). Examination
of this sequence by using the TRANSFAC 5.0 database indi-
cated that it most closely corresponds to a binding site for
homeodomain-containing proteins.
Transgenic analysis of the flk1 intronic element. To test the
functional significance of this element in vivo, we created
transgenic mice expressing -galactosidase under the control
of a 940-bp flk1 5-flanking sequence and the 510-bp intronic
element, with or without a 5-bp mutation (corresponding to
the M4 mutation in Fig. 2B) in the protein-binding element
identified in our footprinting experiments. Transgenic embryos
were analyzed at day 11.0 p.c., i.e., during the critical window
of embryonic blood vessel growth. Consistent with results from
previous studies (24), about half of the transgenic mouse em-
bryos containing the wild-type construct expressed -galacto-
sidase strongly in an endothelium-restricted pattern (Fig. 3A
and B). In contrast, mutation within the footprinted region
abolished reporter gene expression in almost all transgenic
embryos; only 1 of 16 transgenic mice containing the mutated
construct had endothelial cell expression, and in this lone em-
bryo staining was weak and inhomogeneous within the endo-
thelium. These experiments indicate that the footprinted se-
quence is critical for endothelium-specific activation of the flk1
promoter during embryonic development and that the nuclear
protein(s) that interact with this element are likely to play a
key role in the early steps in endothelial cell differentiation.
Identification of HoxB5 binding to the flk1 element in a
genetic screen. We performed a yeast one-hybrid screen to
determine which nuclear protein(s) bound to our footprinted
element. Four tandem integrated copies of this element were
inserted upstream of selection markers in Saccharomyces cer-
evisiae strain YM4271, and a day 10.5 p.c. mouse embryo
library was screened to identify proteins binding this element.
We screened 2  106 clones, and of these five survived selec-
tion. After plasmid rescue and sequencing, three of the five
clones were found to contain full-length cDNA sequence for
the homeobox protein HoxB5 in frame with the Gal4 activa-
tion domain. The specificity of this binding was confirmed in
two assays. First, we measured activation of the lacZ gene by
activation domain fusions in yeast (Fig. 4A). -Galactosidase
activity was only detected when the HoxB5 activation domain
fusion was expressed in yeast containing the wild-type flk1
element upstream of lacZ but not in yeast containing a mu-
tated flk1 element or a p53 binding site. Interestingly, the
strength of the HoxB5 interaction with its cognate element is
greater than that of p53 with its well-characterized response
element, as measured by relative expression of -galactosidase.
Similarly, we performed selection assays in which yeast cells
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grow in media lacking histidine only when activation domain
fusions bind to their specific elements. In this assay, yeast cells
containing the HoxB5 fusion only grew when they contained
the wild-type flk1 element upstream of the selection marker
and not when they contained a mutated element or a nonspe-
cific binding site (Fig. 4B). These results confirm the specificity
of interaction between HoxB5 and the intronic element in the
yeast one-hybrid system.
Although the identification of a homeodomain-containing
protein in this assay was predicted by our TRANSFAC anal-
ysis, neither HoxB5 nor any of the other classical homeobox
proteins have been previously linked with the earliest stages of
FIG. 2. Identification of the minimal DNA sequences in the flk1 intronic enhancer necessary for nuclear protein interactions. (A) Nuclear
protein interactions with the flk1 cis-acting element detected by EMSA. The probe corresponding to bp 150 to 195 of the mouse flk1 first-intronic
enhancer was used to characterize nuclear protein interactions with endothelial and nonendothelial nuclear extracts. The arrow denotes a rapidly
migrating complex, while the asterisk denotes a more intense, slowly migrating complex. (B) Mutant oligonucleotides used in EMSA. Residues that
differ from the wild-type sequence are in boldface. (C) EMSA with C166 nuclear extract with mutant probes described in panel B. (D) Comparison
of partial sequences of the mouse and human flk1 first introns. Identical residues are highlighted, and the nuclear protein-binding site identified
by DNase I footprinting and EMSA is boxed.
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endothelial cell development. However, HoxB5 is expressed in
vascular endothelium (7, 8), and other Hox family members (in
particular, HoxD3 and HoxB3 [8, 31]) have been implicated in
later stages of vessel formation. We confirmed the interaction
between HoxB5 and this element (which we call HBE, HoxB5-
binding element) by EMSA. Unfortunately, a supershifting
antibody for HoxB5 is not available; therefore, we first sought
to determine whether a well-characterized HoxB5 binding se-
quence, LP2 (40), could compete for the binding of nuclear
proteins to the HBE (Fig. 4C). Indeed, excess unlabeled LP2
could compete for nuclear protein binding to the HBE with
nearly or virtually the same efficiency as that of HBE itself. In
contrast, a 4-bp mutation within LP2 (LP2mut), which is
known to weaken the affinity of HoxB5 with LP2, competed
with nuclear protein binding to the HBE much less efficiently.
In addition, we directly tested the ability of HoxB5 to bind to
the HBE by expressing recombinant HoxB5 as a GST fusion
protein. Whereas GST alone did not bind the HBE, the
HoxB5-GST fusion produced a single complex that could be
competed away with excess cold HBE but not with a nonspe-
cific competitor (Fig. 4D). An antibody that recognized GST
retarded the migration of this complex, whereas a nonspecific
antibody had no effect. Therefore, we can confirm specific
HoxB5-HBE interactions in two independent assays.
Trans-activation of the flk1 promoter by HoxB5. To test the
functional consequences of HoxB5 interactions with the HBE,
we performed transient-transfection assays with a luciferase
reporter gene under control of the flk1 promoter and minimal
intronic enhancer in MECs. Expression of HoxB5 potently
transactivated the flk1 promoter in a dose-dependent fashion
(Fig. 5A). To determine whether this effect depends on inter-
actions between HoxB5 and the HBE, we mutated the HBE
within the intronic enhancer. The transactivation activity of
HoxB5 was markedly diminished by mutation of the HBE (Fig.
5B), indicating that HoxB5 mediates the major portion of its
effects on the flk1 promoter through direct interactions with its
cognate element. We tested the specificity of this functional
interaction by comparing the effects of HoxB5 with its cluster
sibling, HoxB6. In contrast to the activity of HoxB5, HoxB6 did
not affect flk1 promoter activity (Fig. 5C). Thus, the interac-
tions of HoxB5 with HBE result in potent and specific trans-
activation of flk1, which suggested to us that HoxB5 plays an
unanticipated role in the early stages of angioblast differenti-
ation from precursors.
Coexpression of HoxB5 and flk1. Although HoxB5 has not
been clearly linked to angioblast differentiation, it is expressed
in lateral plate mesoderm and in somites (28, 45), both of
which are rich sources of endothelial precursors (2, 34). In
addition, HoxB5 has been detected repeatedly in screens for
Hox family members in cultured endothelial cells (7, 8). We
have confirmed that HoxB5 mRNA is expressed in a panel of
embryonic endothelial cell lines (data not shown). To further
explore the developmental relationship between HoxB5 ex-
pression and angioblast development, we utilized differentiat-
ing mouse embryonic stem cell-derived embryoid bodies grown
in attached cultures; the anatomic and molecular events in
embryonic endothelial cell differentiation and blood vessel de-
velopment are faithfully recapitulated in this model (4, 44, 46).
The HoxB5 and flk1 mRNAs first appeared cosynchronously
on day 4 of culture in this model (Fig. 6A). We confirmed
coexpression of flk1 and HoxB5 by sorting cells on day 4 of
culture with an flk1-specific antibody. As demonstrated by
mRNA expression, this antibody sorted cells cleanly into flk1
and flk1 populations (Fig. 6B). HoxB5 mRNA was coex-
pressed with flk1 and was indeed enriched in this cell popula-
tion. Spatiotemporal colocalization of HoxB5 with flk1 pro-
vides additional support for a regulatory role for HoxB5 in
angioblast differentiation.
FIG. 3. The nuclear protein-binding site is required for in vivo activity of the mouse flk1 promoter in transgenic mouse embryos. (A) Repre-
sentative whole-mount -galactosidase-stained E11.0 embryos. Transgenic mouse embryos expressing -galactosidase under control of the flk1
promoter-enhancer stain the vascular endothelium diffusely and strongly. In contrast, a 5-bp mutation within the nuclear protein-binding site
identified by footprinting resulted in the loss of -galactosidase expression in most transgenic embryos. (B) Summary of in vivo activity of the
wild-type and mutant transgenic constructs.
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Enhanced differentiation of angioblasts and definitive endo-
thelial cells by HoxB5. To test the physiologic function of
HoxB5 in flk1 gene regulation and angioblast differentiation,
we examined the effects of manipulating HoxB5 expression on
the number of flk1 cells differentiating in embryoid body
cultures. Because of functional redundancy of Hox family
genes both within paralogous groups and within each Hox
family cluster (12, 38), we felt that underexpression studies
would be less informative, and therefore we chose to stably
overexpress HoxB5 under control of the CMV promoter in
embryonic stem cells prior to differentiation. This approach
has been used previously with success to define the ability of
HoxB4 to expand hematopoietic stem cell populations (21).
We tested at least three independent clones for each condition,
FIG. 4. Identification of HoxB5 binding to the flk1 enhancer in a yeast one-hybrid screen. (A) -Galactosidase assays of clones transfected with
the indicated plasmids grown on synthetic complete medium lacking uracil to test for specific DNA-protein interactions. (B) Yeast transfectants
were grown under growth-resistant conditions (His, Leu, 3-amino-1,2,4-triazole). Growth was detected only in yeast transfected with both the
wild-type flk1 intronic enhancer motif (HBE) and the HoxB5 expression plasmid. (C) EMSA examining the binding of the labeled HBE with
nuclear proteins in C166 cell extract in the presence of excess unlabeled HBE () or with mutant or wild-type HoxB5-binding element LP2 as
marked. (D) EMSA with recombinant GST-HoxB5 (or GST alone) indicating specific binding to the HBE that is competed away by excess specific
() competitor but not by a mutant sequence (NS). In addition, migration of this specific activity is shifted with a GST antibody and not by an
isotypic control antibody (NS). SB, specific binding; SS, supershift.
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and each clone was differentiated at least three times. Over-
expression of HoxB5 mRNA in stable lines was confirmed by
RT-PCR (data not shown). In a representative experiment
after 4 days of differentiation, 17.7% of vector-transfected cells
were detected by the flk1 antibody, whereas the flk1 popula-
tion was expanded to 52.5% in cells overexpressing HoxB5
(Fig. 7A). Similar to the results of our reporter gene assays,
this effect was specific to HoxB5 when cells overexpressing
HoxB5 and HoxB6 were compared (Fig. 7B).
To determine whether activation of flk1 expression by
HoxB5 is sufficient to expand the definitive endothelial popu-
lation in differentiating embryoid bodies, we stained cells that
had been differentiated for 8 days with an anti-PECAM anti-
body, which marks mature endothelial cells at this stage. Con-
sistent with previous observations (46), endothelial cells ar-
range into vessel-like structures at this stage (Fig. 8A). In
HoxB5-overexpressing cells, these structures were markedly
hyperplastic, and the area of the culture covered by endothelial
cells was greatly expanded. We sorted cultures at this stage
with an anti-PECAM antibody to quantify the endothelial cell
compartment. Overexpression of HoxB5 doubled the number
of mature endothelial cells in these cultures, whereas HoxB6
again had no effect (Fig. 8B). Thus, HoxB5 alone is sufficient to
induce angioblast differentiation and expansion of endothelial
FIG. 5. Transactivation of the mouse flk1 promoter-enhancer by HoxB5 in transient-transfection assays. (A) Dose-response analysis of
transactivation of the flk1 promoter-enhancer construct pflk1/en3 by HoxB5. pflk1/en3 (1 g) was transiently transfected with the indicated doses
of pECH/HoxB5 or vector pECH in MECs. pCMV-gal was cotransfected to normalize transfection efficiency. The ratio of luciferase activity to
-galactosidase activity in each sample served as a measure of the normalized luciferase activity. The normalized luciferase activity was expressed
as a percentage of pflk1/en3. (B) The ability of HoxB5 to transactivate the flk1 promoter was examined in the presence or absence of an intact
HBE. HoxB5 (500 ng) was transfected along with wild-type pflk1/en3 () or with a mutant containing a 4-bp mutation in the HBE (■ ). The results
were normalized by cotransfection with pCMV-gal. (C) Comparison of transactivation of the flk1 promoter-enhancer by HoxB5 and its adjacent
cluster mate HoxB6.
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cell populations derived from differentiating embryonic stem
cells.
DISCUSSION
The transition from mesoderm to angioblasts to definitive
endothelium is a highly ordered process, and extracellular sig-
naling events that regulate this differentiation cascade are now
being described in increasing detail—members of the trans-
forming growth factor- superfamily and Indian hedgehog reg-
ulate the earliest stages of endothelial development (9, 15),
and the VEGF and angiopoietin families (among others) con-
trol later stages (19), culminating in the final appearance of a
mature blood vessel. In contrast, the transcriptional events that
direct the different steps in endothelial differentiation are
much less well characterized. This is in contrast to other cell
lineages of similar complexity, for which transcriptional net-
works are being described in detail. Several features of endo-
thelial differentiation contribute to the difficulty in understand-
ing key early transcriptional events. The endothelial lineage
appears early in development and matures rapidly; important
transcriptional regulators may appear transiently and in lim-
ited numbers of cells and yet still may have necessary effects on
lineage determination. There is heterogeneity within the en-
dothelial lineage that is likely determined early in develop-
ment, and different endothelial populations may mature by
somewhat different mechanisms. There is still no consensus on
the developmental steps to maturity of the endothelium; for
example, the extent to which the hemangioblast is a necessary
stage for all endothelial cells during development is as yet
unresolved. Finally, endothelial progenitors may have more
plasticity than has been appreciated previously—under some
circumstances, they retain potential for recommitment to
smooth muscle and cardiomyocyte lineages (13, 51).
We have examined the mechanisms underlying flk1 expres-
sion to identify the earliest transcriptional events in endothelial
cell differentiation. flk1 has several properties that make it
especially well suited as a model of endothelial cell gene reg-
ulation. It is the earliest known marker of the endothelial cell
lineage, its expression is exquisitely restricted to the endothe-
lium and its precursor cells, and its pattern of expression dur-
ing development and in embryonic stem cell differentiation
models is well characterized (32, 50). Here, we have used an
unbiased approach to determine the transcriptional events that
regulate flk1 expression and endothelial cell differentiation by
using both in vitro and in vivo models. A critical element, the
HBE, is located in the 3 portion of the first intron of the flk1
gene. The HBE is necessary for developmental activation of
flk1, and HoxB5 binds and transactivates the flk1 promoter
through this element. Given the size of the DNase I footprints
observed in our studies (Fig. 1), it is possible that HoxB5 binds
to the promoter cooperatively with other, as-yet-unidentified,
transcription factors. Most remarkably, overexpression of
HoxB5 is sufficient to increase the number of early endothelial
precursors and to expand the endothelial population in differ-
entiating embryoid bodies, which recapitulate the important
molecular and morphological events of endothelial cell devel-
opment with fidelity (4, 46).
Hox proteins are transcriptional regulators characterized by
a 60-amino-acid DNA-binding domain, the homeodomain.
The classical Hox proteins exist in four clusters (A through D)
in mammals, with up to 13 Hox genes in each cluster. Their
expression is dictated by temporal colinearity, with more 3
genes expressed before the corresponding 5 genes within a
cluster. Based on studies in both mouse and Drosophila, Hox
proteins are thought to generally regulate pattern formation
and segmental identity along the anterior-posterior axis during
development (36). However, overlapping spatiotemporal ex-
pression and functional redundancy have sometimes made the
assignment of specific functions to individual Hox proteins
problematic. In the case of HoxB5, specific target genes in
mammals have not been clearly defined. The only defect in
HoxB5/ mice is a rostral shift in the shoulder girdle, but
functional redundancy with other family members (possibly the
paralogous Hox proteins A5 and C5) limits the utility of single-
gene deletion for designating function to HoxB5 (38). HoxB5
has been identified in vascular endothelial cells in culture (7,
8), although a specific function in the endothelium (and in
particular a developmental role) has not been previously es-
tablished.
Nevertheless, there is reason to hypothesize a role for Hox
proteins in vascular development and angiogenesis, given the
necessity of pattern formation and tissue remodeling in these
processes. HoxD3 is upregulated in endothelial cells by growth
FIG. 6. Expression of flk1 and HoxB5 mRNA in differentiating
embryoid bodies. (A) To assess the time course of HoxB5 and flk1
mRNA expression, embryoid bodies were differentiated for 2, 4, 6, 8,
or 10 days, and total RNA was extracted from the cells at the indicated
times. The specific genes were detected by RT-PCR. GAPDH served
as an RNA integrity and normalization control. (B) To determine
whether HoxB5 is expressed in flk1 populations, embryoid bodies
were differentiated for 4 days and then sorted into flk1 and flk1
populations. Total RNA was isolated from 106 sorted cells from each
population. RT-PCR analysis demonstrated expression and relative
enrichment of HoxB5 mRNA in the flk1 cell population.
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factor activation and induces a migratory, “invasive” endothe-
lial cell phenotype but not well-formed blood vessels (8). In
contrast, the paralogous gene HoxB3 promotes a later step in
the angiogenic process: capillary morphogenesis (31). Given
the spatiotemporal colinearity of expression and function of
Hox family members, it is reasonable to speculate that other
Hox proteins may participate in vascular developmental pro-
cesses. The identification of HoxB5 as a necessary regulator of
flk1 transcription in our studies provides support for a model in
which the activation of Hox family members contributes to
multiple steps in vascular development.
HoxB4 is the B-cluster member immediately upstream of
HoxB5 in the chain of spatiotemporal expression, so it is in-
formative to consider potential parallels in function between
these two proteins. HoxB4 is expressed in primitive hemato-
poietic stem cells and enhances differentiation of hematopoi-
etic lineages when it is overexpressed in embryonic stem cells
(21), which is analogous to the effects of HoxB5 on endothelial
lineages (Fig. 7 and 8). It is interesting that a role for HoxB4
in hematopoietic function is not suggested by studies of devel-
opmental expression (20) or deletion by homologous recom-
bination (37). Recent reports suggest that HoxB4 facilitates
the transition from primitive to definitive hematopoietic stem
cells and is permissive for ex vivo expansion of adult hemato-
poietic stem cells by inducing a stable state of multipotency (3,
29). The downstream transcriptional targets mediating the ef-
fects of HoxB4 in hematopoietic stem cells are not yet defined.
Taken together with the results presented here, it appears that
HoxB5 acts as part of a pathway in early endothelial lineages
(even possibly at the elusive hemangioblast commitment stage)
that is parallel to that of HoxB4 in the hematopoietic system.
Whether the effects of HoxB5 in our studies reflect increased
differentiation or proliferation of endothelial precursors re-
mains to be determined; such distinctions have often been
difficult to make (18, 25).
Early stages of endothelial cell differentiation from meso-
derm-derived precursors are under strict control, and many
factors—both intrinsic and extrinsic—coordinate this process.
In particular, deletion of numerous growth factors can disrupt
steps within this pathway. For example, lack of a single VEGF
allele severely disrupts differentiation of the endothelium,
leading to embryonic lethality before day 10 p.c. in mice (10)
and arrest of endothelial precursor maturation in embryoid
bodies (6). These and other studies suggest that endothelial
precursors are under strict regulation that is difficult to over-
ride. Surprisingly, endothelium-associated transcription fac-
tors—including SCL/tal-1 and GATA-2—do not elicit expan-
sion of angioblast-derived cells when overexpressed in
mammalian systems, although they may be sufficient to amplify
hematopoietic cell populations (27, 43). These studies indicate
FIG. 7. Increased flk1 cells in embryoid bodies stably expressing HoxB5. (A) Single-cell suspensions were prepared from wild-type or stably
transfected embryoid bodies at day 4, and the expression of flk1 was analyzed by flow cytometry with phycoerythrin-conjugated rat anti-mouse flk1
antibody. The y axis represents the relative cell number; the x axis represents the fluorescence intensity. Gray lines indicate negative control, light
lines represent results obtained with the addition of specific antibody, and dark lines represent the flk1 population. The percentages of cells that
fall within the indicated gate are noted. Values of 
2% represent background staining. A significantly increased number of cells expressing the
mouse flk1 gene were observed in the HoxB5-transfected embryoid bodies. (B) Comparison of flk1 cells in HoxB5- and HoxB6-overexpressing
embryoid bodies.
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that hyperexpansion of endothelial precursors during develop-
ment is restricted at multiple levels. The observation that
HoxB5 is sufficient to increase flk1 precursors and expand
definitive endothelial populations in embryoid bodies is there-
fore a unique cell-intrinsic perturbation of the endothelial dif-
ferentiation pathway. We show here that HoxB5 is a direct
transcriptional activator of flk1 and that it is required for
expression of flk1 in vivo. A careful characterization of
whether the upregulation of flk1 alone is sufficient to trigger
HoxB5-dependent differentiation down the endothelial lin-
eage, whether or not there are other transcriptional targets of
HoxB5 in endothelial precursors, and the cellular phenotypes
of HoxB5-expressing angioblasts will provide a new window
into the events of endothelial cell differentiation.
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